The pharmaceutical industry continues to wrestle with supply chain vulnerability, a problem that has intensified steadily since pandemic-era drug shortages first exposed critical weaknesses.
Geopolitical tensions, tariff uncertainty, and ongoing national security investigations have added fresh pressure to an industry already grappling with overdependence on foreign manufacturing.
Section 232 investigations examining whether foreign pharmaceutical dependency constitutes a national security risk have sharpened boardroom focus across the sector considerably.
The political and commercial will to onshore production is strong, but the economic reality tells a far more complicated story than simply relocating manufacturing back to domestic soil.
Contract development and manufacturing organisations are reporting a rise in enquiries from drug sponsors evaluating domestic production options, yet enquiries and signed contracts remain very different things.
US-based contract manufacturing carries significantly higher costs compared to offshore alternatives, and building fully compliant production capacity is a process measured in years, not months.
Critics of a purely onshoring-focused strategy argue that moving active pharmaceutical ingredient production home without addressing upstream inputs solves only part of the problem.
Key starting materials, excipients, and intermediates sourced from concentrated foreign suppliers mean that essential medicines such as amoxicillin and heparin remain exposed to the same supply risks even after API onshoring.
True supply chain resilience requires qualifying diverse suppliers across multiple geographies and building redundancy well before disruptions occur, rather than scrambling to react after shortages emerge.
Industry analysts caution that two suppliers sharing the same upstream raw material source do not represent genuine diversification, regardless of where their own manufacturing facilities are located.
Building a new large-scale pharmaceutical plant, particularly a sterile injectables facility, typically requires between four and six years from planning to operational status.
Companies still searching for suitable sites in 2026 face the realistic prospect that new plants will not come online until 2028 at the earliest, and in many cases not until 2030.
That timeline mismatch between political urgency and industrial reality is one of the central tensions the industry must confront as governments push for faster domestic self-sufficiency.
Experts increasingly argue that treating global sourcing as a strategic capability, rather than a vulnerability to be eliminated, represents the more practical and resilient long-term approach for pharmaceutical supply chains.